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Anti-Tumoral Effects of Exercise on
Hepatocellular Carcinoma Growth
Uttara Saran,1,2 Maria Guarino,1-3 Sarai Rodrıguez,1,2 Cedric Simillion,4 Matteo Montani,5 Michelangelo Foti ,6
Bostjan Humar,7 Marie V. St-Pierre,1,2 and Jean-Franc¸ois Dufour1,2
Regular physical exercise has many beneﬁcial effects, including antitumor properties, and is associated with a reduced risk
of developing hepatocellular carcinoma (HCC). Less is known about the impact of exercise on HCC growth and progres-
sion. Here, we investigated the effects of exercise on HCC progression and assessed whether any beneﬁcial effects would
be evident under sorafenib treatment and could be mimicked by metformin. American Cancer Institute rats with ortho-
topic syngeneic HCC derived from Morris Hepatoma-3924A cells were randomly assigned to exercise (Exe) and seden-
tary groups, or sorafenib6Exe groups or sorafenib6metformin groups. The Exe groups ran on a motorized treadmill for
60 minutes/day, 5 days/week for 4 weeks. Tumor viable area was decreased by exercise, while cell proliferation and vascu-
lar density were reduced. Exercise increased the expression of phosphatase and tensin homolog deleted from chromosome
10 and increased the phosphorylation of adenosine monophosphate-activated protein kinase, while the phosphorylation of
protein kinase B, S6 ribosomal protein, and signal transducer and activator of transcription 3 were decreased. Transcrip-
tomic analysis suggested major effects of exercise were on nontumoral liver rather than tumor tissue. Exercise demon-
strated similar effects when combined with sorafenib. Moreover, similar effects were observed in the group treated with
sorafenib1metformin, revealing an exercise-mimicking effect of metformin. Conclusion: Exercise attenuates HCC pro-
gression associated with alterations in key signaling pathways, cellular proliferation, tumor vascularization, and necrosis.
These beneﬁcial effects are maintained when combined with sorafenib and can be mimicked by metformin. (Hepatology
Communications 2018;2:607-620)
Regular physical activity (RPA) is a ﬁrst-lineintervention for patients with various chronicdiseases due to its beneﬁcial effects on metab-
olism and the cardiovascular system. The recognition
that RPA protects against cancer and has antitumor
properties has motivated growing interest.(1-3) It is well
established from epidemiologic studies that exercise is
protective against some solid tumors, such as breast,
colon, and prostate cancer, and reduces the cancer risk
and its incidence.(4-6) However, much less is known
about any potential effect of RPA on cancer outcome.
Studies have shown that women diagnosed with breast
carcinoma who exercise regularly live longer and
have less tumor recurrence.(4) Patients with colorectal
Abbreviations: ACC, acetyl coenzyme A carboxylase; AKT, protein kinase B; AMPK, adenosine monophosphate-activated protein kinase; BrdU, bro-
modeoxyuridine; CD, clusters of differentiation; CoA, coenzyme A; DESeq2, Differential Expression Analysis for Sequence Count Data, version 2; Exe,
exercise; FAS, fatty acid synthase; GSEA, gene set enrichment analysis; HCC, hepatocellular carcinoma; Met, metformin; MH, Morris Hepatoma;
mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; PTEN, phosphatase and tensin homolog deleted from
chromosome 10; RPA, regular physical activity; S6-RP, S6 ribosomal protein; Sed, sedentary; Sora, sorafenib; STAT3, signal transducer and activator
of transcription 3; VEGFR, vascular endothelial growth factor receptor.
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carcinoma who undertake RPA have a better outcome
than patients who remain sedentary.(5) The same has
been suggested for patients with prostate cancer.(6)
Studies have reported an association between RPA
and the risk of developing hepatocellular carcinoma
(HCC) whereby exercise signiﬁcantly decreased the
risk.(1-3) In a prospective Taiwanese study, Wen
et al.(1) showed a correlation between the degree of
RPA and the decline of HCC risk; this correlation was
conﬁrmed in a National Institute of Health study.(2)
Moreover, HCC-associated mortality was reported to
be reduced in patients who exercised compared to
inactive ones.(3) The antitumor properties of RPA rely
on multiple mechanisms that are mainly associated
with its beneﬁcial effects on body weight, insulin sensi-
tivity, and chronic inﬂammation.(7) We previously
reported that RPA reduced the risk of developing liver
cancer in a genetic experimental model of nonalcoholic
steatohepatitis-induced HCC.(8) We found that regu-
lar exercise stimulates adenosine monophosphate-
activated protein kinase (AMPK), which phosphory-
lates regulatory-associated protein of mammalian tar-
get of rapamycin (raptor) and in turn inhibits the
mammalian target of rapamycin (mTOR) complex 1
(mTORC1). mTOR functions as a central regulator
for cell proliferation, growth, and survival in response
to growth factors and nutritional status.(9) AMPK
serves as an energy sensor in cells and plays a central
role in linking metabolism and cancer.(7) These two
kinases are regulated by the tumor suppressors phos-
phatase and tensin homolog deleted from chromosome
10 (PTEN) and liver kinase B1, respectively.
It is not clear how RPA inﬂuences the outcome of
HCC after its diagnosis. RPA can reduce mortality
from liver-related diseases,(1) and Koya et al.(10) sug-
gested that exercising signiﬁcantly improved quality of
life without worsening liver function during hospitali-
zation of patients with chronic liver disease and HCC.
Moreover, perioperative physical activity for HCC
patients with liver dysfunction had a beneﬁt to early
resumption after hepatectomy.(11)
Although RPA is a low-cost nonpharmacologic
intervention available to the vast majority of the gen-
eral population, it can be impractical for elderly and
neoplastic patients who have comorbidities and are
poorly mobile. Patients affected by chronic liver dis-
eases and HCC are often too sick to engage in RPA.
Therefore, a drug mimicking the effects of exercise
would be of interest. Metformin, a biguanide drug
widely used to treat type 2 diabetes, activates
AMPK(12) and has been reported to reduce the risk
of developing HCC(13) and the growth of liver
cancer cells, both in vivo and in vitro.(14) As metfor-
min has indirect effects on AMPK, as is also the
case with RPA, it is compelling to compare the
effects of RPA and metformin on HCC growth and
progression.
Currently, the only approved and reimbursed drugs
for HCC treatment are sorafenib (Nexavar) as ﬁrst-
line therapy and regorafenib (Stivarga) as second-line
therapy following sorafenib treatment failure. Sorafe-
nib is an orally active inhibitor of multiple receptor
tyrosine kinases involved in pathways relevant for
tumor growth and angiogenesis, including Raf 1,
B-Raf, vascular endothelial growth factor receptor
(VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-
derived growth factor receptor b. The Asia-Paciﬁc(15)
and Sorafenib Hepatocellular Carcinoma Assessment
Randomized Protocol (SHARP)(16) trials showed an
advantage in overall survival in the sorafenib arm.
Sorafenib does not inhibit AMPK, suggesting possible
beneﬁts from adding physical activity or metformin to
sorafenib.
In light of this background, we investigated 1)
whether RPA reduces HCC progression, 2) whether
this effect is also observed in combination with
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sorafenib therapy, and 3) whether the effects of RPA
can be mimicked by metformin.
Materials and Methods
CELL CULTURE
Morris Hepatoma (MH)-3924A cells were obtained
from the Cell Lines Service (http://clsgmbh.de/) and
cultured in Roswell Park Memorial Institute 1640
media supplemented with 20% fetal bovine serum and
1% penicillin and streptomycin.
ANIMALS AND TUMOR
IMPLANTATION
Experiments were performed with American Cancer
Institute rats obtained from Harlan, KY. Animals were
carefully monitored for the entire duration of the
experiment in adherence with Local Animal Use
Committee guidelines. Tumor implantation was
performed on livers of rats aged 10-12 weeks, as
described.(17)
INTERVENTION PROTOCOL
At the start of the experiment, rats were randomly
assigned to one of six groups (n 5 9 rats/group) within
three sets of experiments: experimental set 1, exercise
(Exe) versus sedentary (Sed); experimental set 2,
exercise1sorafenib (Exe1Sora) versus Sed1Sora; and
experimental set 3, metformin1sorafenib (Met1Sora)
versus Sed1Sora (Supporting Fig. S1). Rats of the
Exe and Exe1Sora groups were gradually introduced
to running on a treadmill (F€orderband GFB-Elmotec,
Kleind€ottingen, Switzerland) by exposing the animals
to increasing treadmill speed for increasing amounts of
exercise time (training acclimatization phase) during
the 6 weeks preceding tumor implantation. Rats of the
Met1Sora groups received metformin 300 mg/kg/day
by oral gavage during the 6 weeks preceding tumor
implantation. After 6 weeks, tumor implantation was
performed on livers of all six experimental groups.
Following a 2-week postsurgical recovery period, Exe
and Exe1Sora rats started running sessions (770 m on
a treadmill, 5 days/week), while Sed and Sed1Sora
rats were kept in their cage for the following 4 weeks.
Rats of the second and third experimental set received
sorafenib 7.5 mg/kg/day by oral gavage for 4 weeks
after the 2-week postsurgical rest. Rats of the
Met1Sora groups received metformin 300 mg/kg/day
by oral gavage for 4 weeks after 2 weeks of postsurgical
rest. At the end of week 6 after tumor implantation, all
rats were killed. Harvesting was performed immedi-
ately after exercise training for the Exe and Exe1Sora
rats (Supporting Fig. S1).
HISTOLOGY AND
IMMUNOHISTOCHEMISTRY
Paraformaldehyde-ﬁxed parafﬁn-embedded tissue
sections were stained with hematoxylin and eosin for
standard microscopy and were evaluated for tumor size
by a pathologist blinded to treatment conditions
(M.M.). For tumor necrosis analysis, cryosections of
tumor tissue were stained with diaminibenzidin as
described.(18) All rats were injected intraperitoneally
with bromodeoxyuridine (BrdU) (50 mg/body weight)
2 hours prior to being killed. BrdU incorporation was
measured using the BrdU in-situ detection kit
obtained from BD Pharmingen (BD Biosciences,
San Jose, CA).
MICROVESSEL DENSITY
Parafﬁn sections were stained with the monoclonal
antibody clusters of differentiation (CD)31 to mark
endothelial cells and blood vessels as described.(19)
Microvessel density was measured blindly.
TISSUE LYSIS AND IMMUNOBLOT
ANALYSIS
Tumor (non-necrotic) and liver tissues were homog-
enized in radio immunoprecipitation assay buffer (150
mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1%
sodium dodecyl sulfate, and 50 mM Tris-HCl pH 7.4)
containing protease and phosphatase inhibitors
(Roche, Rotkreuz, Switzerland). Protein concentration
was measured using the Pierce BCA Protein Assay
(Thermo Fisher Scientiﬁc, Rockford, IL). Immuno-
blots were performed with antibodies against protein
kinase B (AKT; Ser473), signal transducer and
activator of transcription 3 (STAT3), phospho-
STAT3, AMPKa, phospho-AMPKa (Thr172), rap-
tor, phospho-raptor (Ser792), S6-ribosomal protein
(S6-RP), phospho-S6-RP (Ser240/244), fatty acid
synthase (FAS), acetyl-coenzyme A (CoA) carboxylase
(ACC), phospho-ACC (Ser79), 4E-binding protein
1, phospho-4E-binding protein 1, mTOR, vinculin,
and PTEN (Cell Signaling). Signals were analyzed
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using the Bio-1D Advanced software (Vilber-Lourmat,
Marne-la-Vallee, France).
RNA SEQUENCING
Total RNA was extracted from 20 mg of rat tumor
and liver using RNeasy Mini kit (Qiagen, Hombrech-
tikon, Switzerland) following the manufacturer’s
guidelines. Total RNA was analyzed by an Agilent
2100 bioanalyzer using the Agilent RNA 6000 Nano
Kit (Cat# 5067-1511) to ensure the integrity of total
RNA. Messenger RNA was enriched from approxi-
mately 5 lg of total RNA using Dynabeads Messenger
RNA DIRECT Micro Kit (Life Technologies, Carls-
bad, CA), according to the manufacturer’s recom-
mended protocol. Complementary DNA libraries were
then constructed using Ion Total RNA-Seq Kit v2
(Life Technologies) following the manufacturer’s
instructions. Approximately 10 pM of pooled barcoded
libraries were used for templating using Ion PI Tem-
plate OT2 Solutions 200 Kit v3 (Life Technologies) as
per the manufacturer’s recommended protocol. RNA
sequencing and sequence alignment were performed by
PrimBio Research Institute LLC (Exton, PA).
CHARACTERIZATION OF HCC
SUBTYPE
Gene expression analysis and immunoblotting for pro-
tein expression analysis were performed to characterize
the MH-derived HCCs and obtain the molecular sub-
group according to the classiﬁcation by Boyault et al.(20)
PATHWAY ANALYSIS
The output of Differential Expression Analysis for
Sequence Count Data, version 2 (DESeq2) was used
to perform gene set enrichment analysis (GSEA) using
the SetRank method.(21) The algorithm discards gene
sets that have been initially ﬂagged as signiﬁcant if
their signiﬁcance is only due to the overlap with
another gene set. It calculates the P value of a gene set
using the ranking of its genes in the ordered list of P
values as calculated by DESeq2. The following path-
way databases were used during this analysis: BIO-
CYC,(22) Gene Ontology,(23) ITFP,(24) KEGG,(25)
REACTOME,(26) and WikiPathways.(27) Two differ-
ent gene set collections were constructed. The ﬁrst
comprised all gene sets from the aforementioned data-
bases with 250 genes. The second collection con-
tained the gene sets from the previous collection that
showed a signiﬁcant overlap with the union of
10 focus pathways from KEGG: “AMPK signaling
pathway” (rno04152), “regulation of autophagy”
(rno04140), “mTOR signaling pathway” (rno04150),
“phosphoinositide 3-kinase-Akt signaling pathway”
(rno04151), “Jak-STAT signaling pathway” (rno04630),
                                                                 
FIG. 1. Characterization of HCC subtype. (A) Overexpression
of genes (transcriptomic analysis). [mean 6 SD] (B) Phospho-
enzymes (immunoblot density). Abbreviations: AFP, alpha-
fetoprotein; GSK3, glycogen synthase kinase 3; H19, gene for
long noncoding RNA; IGF2, insulin-like growth factor 2;
MYH4, myosin heavy chain IIb; NT, nontumoral tissue; PEG3,
paternally expressed genes 3; RPKM, reads per kilobase million;
SOX9, a transcription factor; T, tumor tissue.
                                                                 
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“peroxisome proliferator-activated receptors signaling
pathway” (rno03320), “mitogen-activated protein
kinase signaling pathway” (rno04010), “Ras signaling
pathway” (rno04014), “VEGF signaling pathway”
(rno04370), and “hypoxia-inducible factor-1 signaling
pathway” (rno04066).
STATISTICAL ANALYSIS
Data are presented as means 6 SD. Data were ana-
lyzed using one-way analysis of variance, Student t
tests, and Tukey post-hoc tests with Sigma Stat pro-
gram version 4. P < 0.05 was considered statistically
signiﬁcant. For the pathway analysis, Fisher’s exact test
was used to determine the signiﬁcance of the overlap,
and a false discovery rate-corrected P value cutoff of
0.05 was applied to retain signiﬁcant sets.
Results
CHARACTERIZATION OF MH-
3924A-DERIVED LIVER TUMORS
Transcriptomic analysis of the MH-orthotopic
tumors revealed overexpression of the following six
classiﬁer genes: myosin heavy chain IIb, transcription
factor SOX9, insulin-like growth factor 2, paternally
expressed genes 3, alpha-fetoprotein, and H19, a
gene for a long noncoding RNA. The protein expres-
sion proﬁle conﬁrmed the overexpression of AKT,
phospho-Akt, and phospho-glycogen synthase kinase
3b. Therefore, MH-derived HCCs are close to the G1
subtype, according to the Boyault classiﬁcation(20)
(Fig. 1).
EFFECT OF EXERCISE ON HCC
GROWTH
In the ﬁrst experimental set testing the effect of
exercise, total tumor volume was not affected by regu-
lar exercise (Fig. 2A), while necrotic areas were larger
in tumors of Exe rats compared with tumors of Sed
rats, indicating decreased viable tumor volume in the
former (Fig. 2B). Photographs of rat HCC tumors are
provided in the Supporting Material (Supporting Fig.
S2). Cell proliferation determined by BrdU staining
was reduced by exercise (Fig. 2C), and immunohisto-
chemistry for CD31 revealed signiﬁcantly less vascular
proﬁles in the tumors of exercised animals compared
with tumors of sedentary animals (Fig. 2D).
                                                                                                                                      
FIG. 2. Effect of exercise on tumor. Effect of exercise on (A) total tumor volume, (B) necrosis and viable tumor volume, (C) cell pro-
liferation, (D) microvessel density. [mean 6 SD] *P < 0.05; **P < 0.01.
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FIG. 3. Effect of exercise on expression and phosphorylation of key signaling proteins. (A,C) Immunoblots for proteins expression
and phosphorylation status in tumor and nontumoral homogenate according to exercise. (B,D) Immunoblots were quantiﬁed and nor-
malized with vinculin. Protein quantiﬁcation was calculated from six samples per group. [mean 6 SD] Western blot images shown
are representative images as each experiment was repeated a minimum of 3 times. *P < 0.05; **P < 0.01. Abbreviations: 4E-BP1,
4E-binding protein 1; LKB1, liver kinase B1; p-4E-BP1, phosphorylated 4E-BP1; p-ACC, phosphorylated ACC; p-Akt, phosphory-
lated Akt; p-AMPK, phosphorylated AMPK; p-S6-RP, phospho-S6-RP; p-STAT3, phosphorylated STAT3.
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FIG. 4. Effect of exercise on gene expression. (A) GSEA performed using the SetRank method. Differential gene expression between
the tumoral and nontumoral liver tissue according to exercise. Red area represents gene expression affected by exercise in nontumoral
liver tissue. Green area represents gene expression affected by exercise in tumoral liver tissue. Blue area represents differential gene
expression between the liver and the tumor affected by exercise. (B) Heatmaps show a gene set collection constructed by the GSEA
in exercised rats compared with sedentary rats. This collection contains gene sets showing a signiﬁcant overlap with the union of 10
focus pathways from the KEGG database. Each column represents a different analysis (effect of exercise in tumoral tissue, effect of
exercise in nontumoral tissue, effect of exercise on the differential expression between tumor and nontumoral tissue). Expression values
are represented by a color scale; “red” indicates high relative expression and “blue” indicates low relative expression. Abbreviations: NF,
nuclear factor; TNF, tumor necrosis factor.
                                                                                                                                      
HEPATOLOGY COMMUNICATIONS, Vol. 2, No. 5, 2018 SARAN ET AL.
613
Immunoblotting analysis of tumor homogenate
demonstrated increased expression of PTEN in exer-
cised animals. Exercise was associated with increased
phosphorylation of AMPK, raptor, and ACC and
with decreased phosphorylation of Akt, S6-RP, and
STAT3 (Fig. 3A,B). The mTOR complex 1 regulator
raptor had a greater degree of phosphorylation at site
Ser792, the target site of AMPK. As the readout of
this signaling pathway, S6-RP was less phosphorylated
in the tumors of exercised rats. Akt was also less phos-
phorylated at the position Ser-473, the target of
mTOR complex 2.
The nontumor liver homogenate of Exe rats showed
an increase in the levels of the tumor suppressor
PTEN, an increase in the phosphorylation status of
AMPK, ACC, and raptor, and a decrease in the phos-
phorylation status of Akt and S6-RP (Fig. 3C,D).
GSEA showed that exercise affected the expression
of signiﬁcantly fewer genes in the tumor compared
with the liver. Considering the differential expression
between liver and tumor, an intermediate number of
genes had their differential expression affected (Fig.
4A). Several pathways were signiﬁcantly altered by
physical activity, as seen for all gene sets from the
TABLE 1. EFFECTS OF EXERCISE ALONE OR IN COMBINATION WITH SORAFENIB, AND
EFFECTS OF METFORMIN ON THE EXPRESSION OF 40 GENES DEFINING A TISSUE
SIGNATURE FOR THE RISK OF HCC
Gene Symbol Prognosis Description Exe Sora1Exe Sora1Met
FSHB Poor Follicle stimulating hormone, beta polypeptide ↘ ↘ ↗
SH3GL2 Poor SH3-domain GRB2-like 2 ↘ ↘ ↘
RBM34 Poor RNA binding motif protein 34 ↘ ↗ ↘
NCAPH Poor non-SMC condensin I complex, subunit H ↗ ↘ ↗
EGF Poor Epidermal growth factor ↘ ↘ ↘
TRIO Poor Uncharacterized protein ↘ ↘ ↘
COL6A3 Poor Protein Col6a3 ↘ ↘ ↘
ABLIM1 Poor LIM domain and actin-binding protein 1 ↘ ↘ ↘
ITGA9 Poor Integrin, alpha 9 ↘ ↘ ↘
NTS Poor Neurotensin ↘ ↘ ↘
SERPINB2 Poor Serpin peptidase inhibitor, clade B (member 2) ↗ ↘ ↗
MMP7 Poor Matrix metallopeptidase 7 ↘ ↘ ↘
PRKG2 Poor 50-AMP-activated protein kinase subunit gamma-2 ↘ ↗ ↗
EDG4 Poor Lysophosphatidic acid receptor 2 ↘ ↘ ↘
NOS2A Poor Nitric oxide synthase 2A ↘ ↘ ↘
EPHA4 Poor Eph receptor A4 precursor ↘ ↘ ↘
SP100 Poor SP100 nuclear antigen ↘ ↘ ↘
FMO1 Poor Flavin containing monooxygenase 1 ↘ ↘ ↘
GPX2 Poor Flutathione peroxidase 2 ↗ ↘ ↗
ATP4B Poor ATPase, H1/K1 exchanging, beta polypeptide ↘ ↘ ↘
% of down-regulated genes 80 85 60
IGF1 Good Insulin-like growth factor I ↗ ↗ ↗
AR Good Androgenic recepor ↗ ↗ ↘
SC5DL Good Sterol-C5-desaturase ↗ ↗ ↘
PLG Good Plasminogen receptor (KT) ↗ ↘ ↗
TXN2 Good Thioredoxin, mitochondrial ↘ ↗ ↘
SCG5 Good Secretogranin V (7B2 protein) ↘ ↘ ↘
CYB5A Good Cytochrome b5 ↗ ↘ ↗
RPS6KA5 Good Ribosomal protein S6 kinase, 90kDa, polypeptide 5 ↗ ↗ ↗
PKLR Good Pyruvate kinase, liver and RBC ↘ ↘ ↘
TMEM97 Good Transmembrane protein 97 ↗ ↗ ↗
PPP1R1A Good Protein phosphatase1,regulatory(inhibitor),subunit 1A ↗ ↗ ↗
PSMB3 Good Proteasome subunit, beta type 3 ↗ ↗ ↗
PTPN2 Good Protein tyrosine phosphatase, non-receptor type 2 ↗ ↘ ↗
ADRA2B Good Adrenergic, alpha-2B-, receptor ↗ ↗ ↘
ACSM3 Good Acyl-CoA synthetase medium-chain family member 3 ↗ ↘ ↗
PFKFB1 Good 6-phosphofructo-2-kinase1 ↗ ↗ ↗
IMPA1 Good Inositol(myo)-1(or 4)-monophosphatase 1 ↘ ↘ ↘
RLF Good Rearranged L-Myc Fusion ↘ ↗ ↘
TTR Good Transthyretin ↗ ↗ ↗
ALDH9A1 Good 4-Trimethylaminobutyraldehyde dehydrogenase ↗ ↗ ↗
% of up-regulated genes 60 60 60
↗, ↘: signiﬁcant differential gene expression (P < 0.05); ↗, ↘: not signiﬁcant differential gene expression.
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FIG. 5. Effect of exercise in sorafenib-treated rats. Effect of exercise1sorafenib versus sedentary1sorafenib on (A) total tumor vol-
ume, (B) necrosis and viable tumor volume, (C) cell proliferation, (D) microvessel density. (E) Immunoblots for protein expression
and phosphorylation status in tumor tissue. (F) Immunoblots were quantiﬁed and normalized with vinculin. Protein quantiﬁcation was
calculated from six samples per group [mean 6 SD]. Western blot images shown are representative images as each experiment was
repeated a minimum of 3 times. *P < 0.05; **P < 0.01. Abbreviations: 4E-BP1, 4E-binding protein 1; LKB1, liver kinase B1; p-4E-
BP1, phosphorylated 4E-BP1; p-ACC, phosphorylated ACC; p-Akt, phosphorylated Akt; p-AMPK, phosphorylated AMPK; p-S6-
RP, phospho-S6-RP; p-STAT3, phosphorylated STAT3.
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databases as well as for the targeted gene sets. Affected
pathways included AMPK signaling, glycerolipid
metabolism, lipid biosynthesis, angiogenesis, apoptosis,
and mTOR signaling (Fig. 4B; Supporting Fig. S3).
We then analyzed the effect of exercise on a tran-
scriptomic signature predictive of HCC recurrence
(derived from nontumoral tissue as described(28)). Reg-
ular exercise reduced the expression of 80% of genes
associated with a higher risk for HCC recurrence and
increased the expression of 60% of genes associated
with less risk of recurrence (Table 1).
EFFECT OF EXERCISE ON
SORAFENIB-TREATED HCC
In the second experimental set, we found that the
effect of exercise in sorafenib-treated animals likewise did
not affect total tumor volume (Fig. 5A). However,
necrotic areas were larger in tumors of Exe1Sora rats
compared with tumors of Sed1Sora rats, indicating
decreased viable tumor volume in the former (Fig. 5B).
Photographs of rat HCC tumors are provided in the
SupportingMaterial (Supporting Fig. S2). Cell prolifera-
tion was reduced by Exe in sorafenib-treated animals
(Fig. 5C), and immunohistochemistry for CD31 revealed
less vascular proﬁles in the tumors of Exe1Sora animals
compared with tumors of Sed1Sora rats (Fig. 5D).
Immunoblotting analysis of tumor homogenate
demonstrated increased expression of PTEN and
decreased expression of FAS in Exe1Sora animals.
Exe1Sora was associated with increased phosphoryla-
tion of AMPK and raptor and with decreased phos-
phorylation of Akt, S6-RP, and STAT3 (Fig. 5E,F).
In Exe1Sora rats, the nontumor liver homogenate
showed an increase in the phosphorylation status of
AMPK, ACC, and raptor and a decrease in the phos-
phorylation status of S6-RP (Supporting Fig. S4).
We analyzed the effect of Exe1Sorafenib on the
transcriptomic signature that was derived from the
nontumor tissue and is predictive of HCC recur-
rence.(28) The association of exercise to sorafenib treat-
ment reduced the expression of 85% of genes
associated with a higher risk for HCC recurrence and
increased the expression of 60% of genes associated
with less risk of recurrence (Table 1).
EFFECT OF METFORMIN ON
SORAFENIB-TREATED HCC
In the third experimental set, we tested the effect of
metformin in sorafenib-treated animals. Total tumor
volume was higher in the sorafenib-treated animals of
this third experimental set (ﬁgure 6A, Sed1Sora) than
in the sorafenib-treated animals of the second experi-
mental set (ﬁgure 5A, Sed1Sora), despite tumor
implantation rules were the same for all six experimen-
tal groups. Because total tumor volume cannot be com-
pared among these three sets of experiments, we
addressed a speciﬁc comparison in each experiment.
Total tumor volume was not signiﬁcantly affected by
metformin in Met1Sora rats (Fig. 6A), even though
necrotic areas were larger in tumors of rats receiving
the combination of sorafenib and metformin; conse-
quently, viable tumor volume was decreased (Fig. 6B).
Photographs of rat HCC tumors are provided in the
Supporting Material (Supporting Fig. S2). Cell prolif-
eration was reduced by metformin in Met1Sora ani-
mals (Fig. 6C), and immunohistochemistry for CD31
revealed signiﬁcantly fewer vascular proﬁles in the
tumors of Met1Sora animals compared with tumors
of Sed1Sora animals (Fig. 6D).
Immunoblotting analysis of tumor homogenate
demonstrated increased expression of PTEN and
decreased expression of FAS in Met1Sora animals.
Met1Sora was associated with increased phosphoryla-
tion of AMPK, ACC, and raptor and with decreased
phosphorylation of Akt and S6-RP (Fig. 6E,F).
In Met1Sora rats, the nontumor liver homogenate
showed an increase in the expression of PTEN, an
increase in the phosphorylation status of AMPK and
ACC, and a decrease in the phosphorylation status of
S6-RP (Supporting Fig. S5).
We then analyzed the effect of Met1Sora on the
transcriptomic signature that was derived from the
nontumor tissue and is predictive of HCC recur-
rence.(28) The association of metformin with sorafenib
treatment reduced the expression of 60% of genes asso-
ciated with a higher risk for HCC recurrence and
increased the expression of 60% of genes associated
with less risk of recurrence (Table 1).
Discussion
In this study we showed that physical activity has
antitumor effects on liver cancer growth in a nonge-
netic nonmetabolic rodent model. Exercise beneﬁts
are maintained in combination with sorafenib, and
metformin mimics these effects when combined with
sorafenib.
Several studies have demonstrated the impact of
moderate physical activity on carcinogenesis,(29-32) and
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FIG. 6. Effect of metformin in sorafenib-treated rats. Effect of metformin1sorafenib versus sedentary1sorafenib on (A) total tumor
volume, (B) necrosis and viable tumor volume, (C) cell proliferation, (D) microvessel density. (E) Immunoblots for protein expression
and phosphorylation status in tumor tissue. (F) Immunoblots were quantiﬁed and normalized with vinculin. Protein quantiﬁcation
was calculated from six samples per group [mean 6 SD]. Western blot images shown are representative images as each experiment
was repeated a minimum of 3 times. *P < 0.05, **P < 0.01. Abbreviations: 4E-BP1, 4E-binding protein 1; LKB1, liver kinase B1;
p-4E-BP1, phosphorylated 4E-BP1; p-ACC, phosphorylated ACC; p-Akt, phosphorylated Akt; p-AMPK, phosphorylated AMPK;
p-S6-RP, phospho-S6-RP; p-STAT3, phosphorylated STAT3.
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data of liver carcinogenesis focus mostly on the role of
exercise in decreasing the risk of developing HCC
than on its impact on HCC progression.(1,2,8) Data
suggest that RPA reduces the risk of developing cancer
and counteracts conditions that increase the risk of
HCC, such as obesity, diabetes mellitus, and nonalco-
holic fatty liver disease,(7) as well as having direct anti-
tumor properties.(33,34) Therefore, RPA may be
considered as an adjuvant approach for cancer thera-
peutic regimens. To date, sorafenib and regorafenib,
two multikinase inhibitors, are the only systemic treat-
ments available for advanced stage HCC, but the sur-
vival beneﬁt is relatively small in most patients(16) and
needs to be further improved. To our knowledge, this
is the ﬁrst study assessing the impact of physical exer-
cise on liver cancer growth, alone or in combination
with sorafenib treatment. In our study, RPA reduced
the viable tumor volume and increased necrosis by
reducing cell proliferation and angiogenesis. These
results establish the positive inﬂuence of moderate
exercise on HCC growth and progression.
The serine/threonine kinase Akt is an upstream pos-
itive regulator of mTOR and its complex mTORC1.
Exercise could counteract HCC progression, in part,
by activating AMPK and thereby impairing mTORC1
activity, particularly in tumors showing hyperactivation
of the Akt pathway.(35) AMPK disrupts the binding
of mTOR and raptor, resulting in reduction of
mTORC1 activity.(36) Therefore, AMPK activation
has antitumor effects downstream of Akt.(37) MH-
implanted tumors demonstrated an increased expres-
sion of alpha-fetoprotein, H19, insulin-like growth
factor 2, myosin heavy chain IIb, transcription factor
SOX9, and paternally expressed genes 3, which char-
acterize the G1 subtype of the classiﬁcation proposed
by Boyault et al.(20) G1 HCCs display high chromo-
somal instability, overexpression of genes expressed in
fetal liver, and an activation of the AKT pathway.
The tumor suppressor PTEN was identiﬁed as a
functional target of RPA by showing increased expres-
sion in the tumor of Exe rats. Loss of PTEN results in
the activation of AKT kinases, which play key roles in
cell growth, proliferation, and invasion.(8) In contrast,
the expression of STAT3 decreased in exercised rats.
STAT3 is a downstream factor of mTOR and plays a
role in cancer angiogenesis and metastasis. Preventing
the activation of STAT3 may inhibit the growth of
HCC.(38) Phosphorylation of AMPK was increased by
RPA, suggesting increased activity of this kinase,
which was conﬁrmed by increased phosphorylation of
its substrate ACC. Phosphorylation of AMPK leads to
the phosphorylation and inactivation of ACC, which
is an important regulatory enzyme in the synthesis of
fatty acids by de novo lipogenesis.(39) ACC catalyzes
the conversion of acetyl-CoA to malonyl-CoA. The
inhibition of ACC by phosphorylated AMPK reduces
the substrates for FAS, leading to decreased FAS
activity. Elevated levels of FAS have been reported in
cells derived from several cancers, such as colon, pros-
tate, breast, and ovarian, and the inhibition of FAS has
been reported to attenuate growth of cancer cells and
to induce apoptosis.(40)
GSEA revealed that the effects of exercise attenu-
ated the expression of many more transcripts in nontu-
mor liver compartments than in the corresponding
tumor compartments, with activation of several path-
ways in nontumor tissue, including AMPK signaling,
lipid metabolism, angiogenesis, and apoptotic signal-
ing. The main impact of exercise is on the tumor envi-
ronment rather than on the tumor itself. HCC is a
cancer characterized by a close relationship between
the tumor environment and cancer growth. Several
angiogenesis factors are more expressed in nontumor
liver tissue than in HCC,(41) for example, interleukin-
2 and interleukin-15.(42) These ﬁndings show that
both tumor and nontumor environments have a role in
the progression of HCC. Taken together, our results
suggest that RPA exerts beneﬁcial effects on reducing
liver cancer growth and progression by mechanisms
involving molecular pathways in both tumor and non-
tumor liver tissue.
The possibility that RPA may have additive antitu-
mor effects with sorafenib was explored. The combina-
tion of exercise with sorafenib decreased cell
proliferation, microvessel density, and viable tumor
volume when compared with sorafenib without exer-
cise, showing an additive effect of RPA on sorafenib
therapy. Phosphoinositide 3-kinase/AKT/mTOR
pathway evaluation revealed a similar proﬁle to that of
exercise alone. These results suggest that RPA may act
as an adjuvant to sorafenib therapy in patients with
HCC.
Metformin is widely prescribed as an oral antidia-
betic drug. It has been recognized that it also has anti-
tumor properties. Metformin leads to activation of
AMPK, which is a mechanism of action similar to
RPA.(43-45) Accordingly, several studies suggested that
metformin enhances the oncologic action of sorafenib.
Metformin in combination with sorafenib prevented
HCC recurrence in mice after surgical resection.(46)
Metformin inhibited HCC cell migration and invasion
and enhanced the antimetastatic effect of sorafenib.(47)
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It improved the efﬁcacy of sorafenib by activating the
AMPK pathway.(48) The combination of metformin
and sorafenib inhibited the proliferation of HCC in
vitro and in vivo and had a synergistic antiproliferative
effect.(49) Our results conﬁrm that metformin can pro-
vide additive beneﬁts to sorafenib, with a signiﬁcant
reduction in cell proliferation and angiogenesis, by
affecting similar molecular pathways as RPA. This is
interesting because patients with HCC can be too sick
to exercise regularly and metformin may provide a
pharmacologic effect mimicking RPA, as suggested by
Linden et al.(50) who showed that combining metfor-
min and exercise did not yield added beneﬁts.
RPA has a beneﬁcial impact on the predictive tran-
scriptomic signature reported by Hoshida et al.(28) by
down-regulating most of the genes associated with
poor survival and up-regulating most of those associ-
ated with good prognosis. Similar effects were
observed with the association of exercise with sorafenib
and metformin with sorafenib. These ﬁndings further
suggest the potential role of exercise in ameliorating
the outcome of patients with HCC.
In conclusion, our results suggest that HCC pro-
gression is attenuated by RPA and that this effect is
also apparent in combination with sorafenib and could
be eventually substituted by metformin.
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